CTLA4 has been shown to outcompete T cell co-stimulatory receptor, CD28 to bind CD80 and CD86 ligands, and creating an immunosuppressive environment which is conducive to tumor growth (Pardoll, 2012). Here, CTLA4 is linked to neoplasm.